TORONTO, ON, April 16, 2026

PharmaTher Holdings Ltd. has announced its strong support for proposed U.S. regulatory reclassification of therapeutic peptides, a move that could significantly expand the commercial potential of its PharmaPatch™ microneedle delivery platform and PatchPrint™ manufacturing technology. The company emphasized that evolving regulatory policies could unlock new opportunities in peptide-based therapeutics, positioning PharmaTher at the forefront of next-generation drug delivery innovation.

Regulatory Shift Could Expand Peptide Market Opportunities

PharmaTher highlighted that ongoing U.S. Food and Drug Administration (FDA) review processes, including the upcoming Pharmacy Compounding Advisory Committee meeting in July 2026, may redefine how certain peptides are regulated and accessed. The review includes key peptide candidates such as BPC-157, KPV, TB-500, and MOTs-C, which are already part of PharmaTher’s strategic development roadmap.

The company believes that a more accessible and medically supervised regulatory framework could significantly expand the addressable market for peptide therapies. This shift is expected to benefit both patients and healthcare providers, while enabling companies like PharmaTher to accelerate innovation in peptide delivery systems and formulation technologies. Importantly, the alignment between regulatory focus areas and PharmaTher’s existing pipeline strengthens its competitive positioning in the evolving peptide therapeutics landscape.

Microneedle Platform Drives Drug Delivery Innovation

Advertisement

cGxPJobs Banner

At the core of PharmaTher’s strategy is its PharmaPatch™ microneedle platform, designed to deliver peptides through a non-invasive, needle-free transdermal system. This approach offers key advantages, including improved patient compliance, enhanced convenience, and flexible dosing options, making it highly attractive for chronic and outpatient therapies.

Complementing this is the company’s PatchPrint™ automated manufacturing platform, which enables scalable production of microneedle patches in a compact, programmable format suitable for pharmaceutical companies, hospitals, and compounding pharmacies. The platform’s ability to support end-to-end peptide patch manufacturing positions it as a valuable tool in expanding peptide-based treatment applications.

PharmaTher also recently strengthened its innovation pipeline with a U.S. provisional patent application focused on stabilized peptide formulations, ensuring improved stability during manufacturing, storage, and use. This integrated approach—combining delivery technology, manufacturing capability, and intellectual property—creates a robust foundation for future growth.

Integrated Strategy Enhances Commercial and Clinical Potential

PharmaTher’s strategy integrates product development, manufacturing innovation, and regulatory alignment, creating a comprehensive ecosystem for peptide therapeutics. The company believes that as regulatory clarity improves, its combined platforms—PharmaPatch™ for product delivery and PatchPrint™ for manufacturing—will enable rapid commercialization and strategic partnerships across multiple healthcare sectors.

The potential expansion of peptide access could also open opportunities in compounding pharmacies and decentralized healthcare settings, where scalable and adaptable manufacturing solutions are increasingly valuable. PharmaTher’s positioning allows it to address both proprietary product development and third-party collaboration opportunities, further strengthening its market presence.

While the regulatory process remains ongoing, the company views current developments as a critical external catalyst supporting its long-term growth strategy, particularly in the rapidly evolving field of peptide therapeutics and advanced drug delivery systems.

Implications for Pharma Innovation and Regulatory Landscape

The proposed peptide reclassification reflects a broader trend toward modernizing regulatory frameworks to support emerging therapeutic modalities, including peptides and biologics. As demand for targeted, patient-friendly therapies continues to grow, innovations in delivery technologies such as microneedle patches are expected to play a crucial role in improving treatment accessibility and adherence.

PharmaTher’s approach underscores the importance of aligning scientific innovation with regulatory evolution, ensuring that new therapies can be developed and delivered within GxP-compliant frameworks. By focusing on integrated platforms and scalable technologies, the company is contributing to the advancement of precision medicine and next-generation pharmaceutical solutions.

The PharmaTher announcement highlights a strategic convergence of regulatory opportunity and technological innovation, positioning the company to capitalize on potential changes in the peptide therapeutics landscape. With strong alignment between its pipeline, manufacturing platforms, and intellectual property strategy, PharmaTher is well-positioned to drive growth in non-invasive drug delivery and peptide-based therapies, reinforcing its role in shaping the future of pharmaceutical development.

Source: PharmaTher press release